Literature DB >> 23975306

DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) guidelines.

Patricia Wehner1, Michael D Lagios, Melvin J Silverstein.   

Abstract

BACKGROUND: In 2008, the NCCN published guidelines allowing low-risk DCIS patients to be treated by excision alone. The goal of this study was to determine local and distant recurrence and breast-cancer specific survival in patients with DCIS that meet NCCN criteria and are treated with excision alone.
METHODS: A prospective, single institution database was analyzed for patients with the following: pure ductal carcinoma in situ (no microinvasion), tumor extent 20 mm or less, age ≥50 years, margin width ≥2 mm, and nuclear grade 1 or 2 (non-high grade). Patients were treated with excision alone. Kaplan-Meier analysis was used to determine recurrence and survival rates.
RESULTS: A total of 205 patients were treated with excision alone. The median age was 59 years. The median time of follow-up was 51 months. The median extent of disease was 8 mm. There were a total of nine local recurrences. The 6-year probability of local recurrence was 6.6 %. The 12-year probability of local recurrence was 7.8 %. The 12-year breast cancer-specific survival probability was 100 %.
CONCLUSIONS: The 12-year local recurrence rate for DCIS patients in NSABP Protocol B-17 treated with excision alone was 32 %, and for excision plus radiation therapy, it was 16 %. In this study, retrospectively applying the NCCN Guidelines to our patients, the 12-year local recurrence rate for excision alone was 7.8 %. Patients with a low risk of local recurrence, if treated by excision alone, can be safely selected using the NCCN Guidelines.

Entities:  

Mesh:

Year:  2013        PMID: 23975306     DOI: 10.1245/s10434-013-3176-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Ductal Carcinoma In Situ: Treatment Update and Current Trends.

Authors:  Katrina B Mitchell; Henry Kuerer
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

2.  Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.

Authors:  Meghan R Flanagan; Mara H Rendi; Vijayakrishna K Gadi; Kristine E Calhoun; Kenneth W Gow; Sara H Javid
Journal:  Ann Surg Oncol       Date:  2015-07-23       Impact factor: 5.344

Review 3.  Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients.

Authors:  Chirag Shah; Frank A Vicini; Sameer Berry; Thomas B Julian; John Ben Wilkinson; Simona F Shaitelman; Atif Khan; Steven E Finkelstein; Neal Goldstein
Journal:  Am J Clin Oncol       Date:  2015-10       Impact factor: 2.339

Review 4.  Margins in breast cancer: How much is enough?

Authors:  Melissa Pilewskie; Monica Morrow
Journal:  Cancer       Date:  2018-01-16       Impact factor: 6.860

5.  Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study.

Authors:  Yasuaki Sagara; Rachel A Freedman; Ines Vaz-Luis; Melissa Anne Mallory; Stephanie M Wong; Fatih Aydogan; Stephen DeSantis; William T Barry; Mehra Golshan
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

6.  A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast.

Authors:  Luca Nicosia; Anna Carla Bozzini; Silvia Penco; Chiara Trentin; Maria Pizzamiglio; Matteo Lazzeroni; Germana Lissidini; Paolo Veronesi; Gabriel Farante; Samuele Frassoni; Vincenzo Bagnardi; Cristiana Fodor; Nicola Fusco; Elham Sajjadi; Enrico Cassano; Filippo Pesapane
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.